New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #COVID19research--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19” were published Feb. 20 on medRxiv, a preprint publication website. The Phase 3 study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving an added nutritional protocol. Aimed at improving mitochondrial function, the proto

Click to view original post